Enabling Expedited Review Programs for Novel Drugs through Upstream Supply Chain Readiness

Is your novel drug on its way through an expedited review program? Is every segment of your pharmaceutical supply chain ready for regulatory scrutiny? Upstream intermediates and regulatory starting materials are often neglected. Learn from industry experts Dr. Valdas Jurkauskas, VP of Technical Operations at Black Diamond Therapeutics, and Dr. Ke Chen, VP of Process Research & Development at WuXi STA as they discuss the best approaches to enabling expedited review programs through case studies on upstream supply chain readiness.
Access on-demand webinars & videos